Edition:
United States

Profile: OncoCyte Corp (OCX)

OCX on American Stock Exchange

2.01USD
20 Aug 2019
Change (% chg)

$0.04 (+2.03%)
Prev Close
$1.97
Open
$1.97
Day's High
$2.05
Day's Low
$1.96
Volume
28,740
Avg. Vol
308,619
52-wk High
$6.92
52-wk Low
$1.16

OncoCyte Corporation (OncoCyte), incorporated on September 30, 2009, is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient.

The Company's diagnostic tests (lung, breast and bladder cancer tests) are in the assay development-stage. The Company is collaborating with The Wistar Institute of Anatomy and Biology (Wistar) to develop the confirmatory lung cancer diagnostic test in a multi-site clinical study evaluating the blood-based lung cancer diagnostic test. OncoCyte is developing a confirmatory diagnostic test that could be used with women who have an indeterminate mammogram result (Breast Imaging-Reporting and Data System ((BI-RADS) 3 or 4). Its breast confirmatory diagnostic could be incorporated into breast screening protocols to confirm whether women with BI-RADS 3 or 4 scores need to undergo additional imaging or an invasive biopsy. As part of its clinical development of a urine-based bladder cancer diagnostic test, the Company has initiated a clinical trial that has been expanded to a multi-site trial. Its operations include planning and launching research and diagnostic test development programs in house and with partners, pursuing patents and conducting clinical trials.

Company Address

OncoCyte Corp

1010 Atlantic Ave Ste 102
ALAMEDA   CA   94501-1147
P: +1510.7750515
F: +1510.5213389

Company Web Links